Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind Study to Scrutinize the Efficacy of Secukinumab in Patients With Moderate to Severe Atopic Dermatitis

NCT03568136 is registered in ClinicalTrials.gov with GWT-TUD GmbH as lead sponsor.

NCT NCT03568136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03568136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind Study to Scrutinize the Efficacy of Secukinumab in Patients With Moderate to Severe Atopic Dermatitis
Lead sponsor
GWT-TUD GmbH
Phase
Phase 2
Overall status
Completed
Start date
September 18, 2018
Completion date
May 4, 2020
Enrollment
22 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, atopic, eczema, atopic, neurodermatitis, atopic